Apollo Medical Holdings, Inc. Receives NCQA's HEDIS Health Plan Measure Certification for Measurement Year 2023

ALHAMBRA, Calif., June 22, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that it received certification from the National Committee for Quality Assurance ("NCQA") Healthcare Effectiveness Data and Information Set ("HEDIS®") Health Plan Measure Certification Program™. It is the second year in which the Company has received this certification, and in measurement year 2023, ApolloMed expanded its certification from 5 to 20 measures, covering the most widely used HEDIS measures in the managed care industry.

NCQA (www.ncqa.org) is an independent, non-profit organization that accredits and certifies a wide range of healthcare organizations and manages the evolution of HEDIS, the healthcare quality measurement tool used by more than 90 percent of health plans in the United States, covering 200 million people.

This certification allows ApolloMed to provide services that align with the industry's most rigorous clinical quality measurement processes, resulting in more accurate and timely identification of eligible members and services. ApolloMed designed and implemented its HEDIS engine as a RESTful API to work in an interoperable way with other data engines and technologies, increasing the measure outputs' transparency, interpretability, and usability. 

Kevin Buchan, Jr., Ph.D., AVP of Analytics at ApolloMed, said, "We are very excited about this measurement year's certification from NCQA. We have continued to improve our engine over the last year, but for the first time, we are ready to offer our HEDIS engine via RESTful API to our partners. We look forward to helping other value-based and digital health organizations benefit from real-time, accurate care quality measures."

Yubin Park, Ph.D., Chief Data and Analytics Officer at ApolloMed, stated, "We are pleased to add our RESTful API interface for HEDIS measures to our analytics platform, which also includes our social determinants of health analytics tool and risk insights tool. We are strong believers in equitable access to high-quality, culturally competent healthcare for all, and remain committed to building technologies that will help lower administrative costs while improving operating efficiencies, quality of care, and access to care. Technology investments such as this allow us to reinvest more into best-in-class patient care and our provider partners, a virtuous cycle that we are excited to further accelerate."

In 2023, ApolloMed was certified by the NCQA HEDIS Health Plan Measure Certification Program™ for 20 different measures. This year's certified measures include key diabetes measures, such as Hemoglobin A1c Control for Patients with Diabetes (HBD), Blood Pressure Control for Patients with Diabetes (BPD), Eye Exam for Patients with Diabetes (EED), Kidney Health Evaluation for Patients with Diabetes (KED), and 16 other measures. 

HEDIS® is a registered trademark of NCQA. NCQA HEDIS Health Plan Measure Certification Program™ is a trademark of NCQA.

About Apollo Medical Holdings, Inc.
ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.

Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and entities participating in the Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation models. For more information, please visit www.apollomed.net.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company's operational focus and strategic growth plans. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the Securities and Exchange Commission ("SEC"), including without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC and any subsequent quarterly reports on Form 10-Q.

FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
(626) 943-6491
investors@apollomed.net

Carolyne Sohn, The Equity Group
(408) 538-4577
csohn@equityny.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/apollo-medical-holdings-inc-receives-ncqas-hedis-health-plan-measure-certification-for-measurement-year-2023-301857525.html

SOURCE Apollo Medical Holdings, Inc.